These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38892423)

  • 21. Autophagy, NAFLD and NAFLD-Related HCC.
    Wu WKK; Zhang L; Chan MTV
    Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sympathetic and parasympathetic innervation in hepatocellular carcinoma.
    Zhang L; Wu LL; Huan HB; Chen XJ; Wen XD; Yang DP; Xia F
    Neoplasma; 2017; 64(6):840-846. PubMed ID: 28895408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver.
    Ko M; Kamimura K; Owaki T; Nagoya T; Sakai N; Nagayama I; Niwa Y; Shibata O; Oda C; Morita S; Kimura A; Inoue R; Setsu T; Sakamaki A; Yokoo T; Terai S
    Dis Model Mech; 2021 Mar; 14(3):. PubMed ID: 33787507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.
    Gori M; Arciello M; Balsano C
    Biomed Res Int; 2014; 2014():741465. PubMed ID: 24745023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent progress in the emerging role of exosome in hepatocellular carcinoma.
    Abudoureyimu M; Zhou H; Zhi Y; Wang T; Feng B; Wang R; Chu X
    Cell Prolif; 2019 Mar; 52(2):e12541. PubMed ID: 30397975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
    Michael C; Martínez-Navarro FJ; de Oliveira S
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of aging in the progression of NAFLD to HCC.
    He Y; Su Y; Duan C; Wang S; He W; Zhang Y; An X; He M
    Ageing Res Rev; 2023 Feb; 84():101833. PubMed ID: 36565959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
    Ruf B; Heinrich B; Greten TF
    Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NAFLD Related-HCC: The Relationship with Metabolic Disorders.
    Zhang X
    Adv Exp Med Biol; 2018; 1061():55-62. PubMed ID: 29956206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
    Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
    Front Immunol; 2020; 11():627424. PubMed ID: 33603757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
    Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
    BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.
    Adolph TE; Grander C; Grabherr F; Tilg H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.